Market research
KNE.V Kane Biotech Inc
V CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.31
Profile
Company facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA4838092084
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.31
About
About Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio includes antimicrobial wound gel, antimicrobial wound gel spray, and antimicrobial wound rinse under revyve name, as well as antimicrobial surgical hydrogel under coactiv+ name. In addition, the company offers scalp detoxifier product line under the Omni Bioceuticals brand. Further, it engages in developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; revyve Antimicrobial Wound Rinse for use in acute and chronic wounds; DispersinB Hydrogel for use in surgical/acute wounds; and DispersinB Acne Cleanser for use in the treatment of mild to moderate acne vulgaris. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the KNE.V discussion.
5 years, 5 months ago
Kane Biotech Inc is currently in a long term uptrend where the price is trading 20.3% above its 200 day moving average.
From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.6.
Kane Biotech Inc's total revenue sank by 36.1% to $361K since the same quarter in the previous year.
Its net income has increased by 10.9% to $-1M since the same quarter in the previous year.
Finally, its free cash flow fell by 66.6% to $-2M since the same quarter in the previous year.
Based on the above factors, Kane Biotech Inc gets an overall score of 3/5.